Susan Galbraith, EVP Oncology Haematology R&D

Lorem ipsum dolor sit amet

Susan Galbraith is the Executive Vice President of Oncology Haematology R&D at AstraZeneca, with global accountability for the Oncology portfolio from discovery through to late-stage development. Susan is helping transform the productivity and scientific output from Oncology R&D, leading the charge for exploring the next wave of cancer treatment regimens, including therapies that directly target cancer cells, others that harness the potential of the immune system, and novel combinations that may result in deeper, more durable responses. To date, Susan has been instrumental in bringing 13 cancer medicines to patients. 

A Clinical Oncologist by background, Susan trained in medicine at Manchester and Cambridge Universities and has a PhD from the University of London. In recognition of her contributions to Oncology drug development, she was awarded an honorary Doctorate of Medical Science from the Institute of Cancer Research (ICR) in 2017, admitted to Fellowship of the Academy of Medical Sciences in 2018 and elected to the Academy of the American Association for Cancer Research (AACR) in 2024.

Susan is well known in the scientific community for her thought leadership and collaboration with clinicians, academic physicians, governments and the broader pharmaceutical industry. In addition to her role with AstraZeneca, Susan is a member of the Cambridge Cancer Centre Executive Committee and the Scientific Advisory Board of the ICR. From 2021-2024 she served on the Board of Directors of the AACR and currently serves on the European Association of Cancer Research (EACR) Advisory Council.

Discover how Susan Galbraith is driving innovation in cancer research

By attacking cancer from multiple angles, treating earlier and smarter, and harnessing potentially transformational technologies, we are helping transform outcomes and moving towards our ambition of one day eliminating cancer as a cause of death.

Susan Galbraith Executive Vice President, Oncology Haematology R&D, AstraZeneca

Publications

From drug development in cancer medicines to diversity in clinical trials, discover the topics Susan has recently contributed to in leading scientific journals.

Collaborators: Tolulope Adewole, Bjorn Albrecht, Shaalan Beg, Otis Brawley, I-Fen Chang, Bobby Daly, Angelo de Claro, Jennifer Dent, Maura Dickler, Abasi Ene-Obong, Lola Fashoyin-Aje, Justin Finnegan, Susan Galbraith, Mary Gospodarowicz, Julie Gralow, Tufia Haddad, Chitkala Kalidas, Artur Katz, Karen Kaucic, Harriet Keane, Mark Lanasa, Jeff Legos, Bob T Li, Jennifer Mills, Stefan Oelrich, Stefan Olopade, John Palma, Richard Pazdur, Piotr Pilarski, Jing Qian, Kevin Rudd, Sepideh Shokrpour, Craig Tendler, Matt Wilson, Victoria W Smart, Yi-Long Wu, James Yan, Lianshan Zhang, Diya Li, Johanna Shen, Amy Silverstein, Ghassan Abou-Alfa, Shelly Anderson, Patrick Beyrer, Danielle Carnival, Stephen Clarke, Terri Conneran, Lisa M DeAngelis, Connie Diakos, Luis Diaz, Carlos Henrique Dos Anjos, Jeffrey A Drebin, Debra Eisenmen, Russell Flannery, David Fredrickson, James M Isbell, David R Jones, Adedayo Joseph, Caroline Kennedy, T Peter Kingham, Adrian Lee, Nancy Y Lee, Lillian Leigh, Zhi-Zhong Li, An-Wen Liu, Dazhi Liu, Si-Yang Liu, Si-Yang Maggie Liu, Vicky Makker, Meritxell Mallafre-Larrosa, Sean McBride, Isabel Mestres, Sebastian Mondaca, Paulo Nigro, Larry Norton, John V Oyler, Nick Pavlakis, Simon Powell, Bruce Robinson, Yi Qin, Pedram Razavi, Jorge Reis-Filho, Gaetano Rocco, Charles M Rudin, Orville Schell, Howard I Scher, Deborah Schrag, Greg Simon, Dorrance Smith, Morgan Speece, Hai-Yan Tu, Aminu Umar-Sadiq, Bu-Hai Wang, Helen Wheeler, Chong-Rui Xu, Li-Xu Yan, Fan Yang, Byeong Yoon, Catharine Young, Jia-Tao Zhang, Qing Zhou.

Bloomberg New Economy International Cancer Coalition; McKinsey Cancer Center; Cure4Cancer. Advancing Global Health Equity in Oncology Clinical Trial Access. Cancer Discov. 2024 Dec 2;14(12):2317-2323. doi: 10.1158/2159-8290.CD-24-1288. PMID: 39315831.

Reis-Filho JS, Scaltriti M, Kapil A, Sade H, Galbraith S. Shifting the paradigm in personalized cancer care through next-generation therapeutics and computational pathology. Mol Oncol. 2024 Aug 30;18(11):2607-2611. doi: 10.1002/1878-0261.13724. PMID: 39214683.

Cabrera C, Fernández-Llaneza D, Ghazoui Z, D'Abrantes S, Esparza-Franco MA, Sopp C, Maj B, Chiou VL, Valastro B, Pangalos MN, Galbraith S, Ghiorghiu S, Massacesi C. Diversity of US participants in AstraZeneca-sponsored clinical trials. Contemp Clin Trials. 2024 Mar 11. doi: 10.1016/j.cct.2024.107496.

Durán CO, Bonam M, Björk E, Hughes R, Ghiorghiu S, Massacesi C, Campbell A, Hutchison E, Pangalos MN, Galbraith S. Implementation of digital health technology in clinical trials: the 6R framework. Nat Med. 2023 Nov;29(11):2693-2697. doi: 10.1038/s41591-023-02489-z. PMID: 37587220.

Reynolds AR, Moschetta M, Yohannes AR, Walcott F, Ashford M, Szucs Z, Sarbajna T, Hadfield J, Harrison E, Challis BG, Hernandez AG, Schiavon G, Germa C, Zorenyi G, Crean B, Galbraith S. A View on Drug Development for Cancer Prevention. Cancer Discov. 2023 May 4;13(5):1058-1083. doi: 10.1158/2159-8290.CD-22-0776. PMID: 37067191.

Lazar V, Girard N, Raymond E, Martini JF, Galbraith S, Raynaud J, Bresson C, Solomon B, Magidi S, Nechushtan H, Onn A, Berger R, Chen H, Al-Omari A, Ikeda S, Lassen U, Sekacheva M, Felip E, Tabernero J, Batist G, Spatz A, Pramesh CS, Girard P, Blay JY, Philip T, Berindan-Neagoe I, Porgador A, Rubin E, Kurzrock R, Schilsky RL. Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Non-Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precis Oncol. 2022 Sep;6:e2200072. doi: 10.1200/PO.22.00072. PMID: 36108261; PMCID: PMC9489166.

Gill SJ, Wijnhoven PWG, Fok JHL, Lloyd RL, Cairns J, Armenia J, Nikkilä J, Lau A, Bakkenist CJ, Galbraith S, Vens C, O'Connor MJ. Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development. Mol Cancer Ther. 2021 Sep;20(9):1614-1626. doi: 10.1158/1535-7163.MCT-20-0502. Epub 2021 Jun 22. PMID: 34158341; PMCID: PMC8650722.